NCT04039230 2026-03-16
Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.
Massachusetts General Hospital
Phase 1/2 Active not recruiting
Clinical Trials
10 trialsNCT06963905 2026-02-17
SIMONE
Yale University
Phase 1/2 Recruiting
NCT04863885 2025-12-17
Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Active not recruiting
NCT06238921 2025-12-05
Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Recruiting
NCT06612203 2025-12-05
WIN-B
MedSIR
Phase 1/2 Active not recruiting
NCT06040970 2025-12-02
Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer
Icahn School of Medicine at Mount Sinai
Phase 1/2 Recruiting
NCT04724018 2025-11-04
Sacituzumab Govitecan Plus EV in Metastatic UC
Dana-Farber Cancer Institute
Phase 1/2 Recruiting
NCT07011654 2025-10-23
Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT06462092 2025-09-29
Sacituzumab Govitecan and Intrathecal Chemotherapy for Treating Leptomeningeal Metastases From Her2-negative Breast Cancer
Guangzhou Medical University
Phase 1/2 Recruiting
NCT06328387 2024-03-25
HCQ+ADC vs ADC in the Treatment of Advanced Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 1/2 Recruiting